JOACHIM BOEHLER, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Sawin and colleagues (1) conclude in their recent article, "In the meantime [until the thyroxine content is known to be as stated], a reasonable course would be to use an oral thyroxine preparation that is known to contain approximately its stated content."
I question the basis and ethics (2) of this conclusion favoring a switch to Levothroid (Armour Pharmaceutical Co., Kankakee, Illinois). A switch to a more potent thyroid preparation might be dangerous for patients who have reached a steady state on their current regimen. Ramos-Gabatin (3) found not only the expected change in thyroid function tests
BOEHLER J. Oral Thyroxine. Ann Intern Med. 1984;101:572–573. doi: 10.7326/0003-4819-101-4-572
Download citation file:
Published: Ann Intern Med. 1984;101(4):572-573.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use